611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
New, Natural Pesticides Effective Against Mosquitoes: StudyDoctors Not Talking About Newer Meningitis VaccineAHA: 'Bad' Cholesterol Can Be Deadly in Otherwise Healthy PeopleHealth Tip: Keep Your Bladder Healthier4 Ways to Protect Your Child From Allergic Reactions at SchoolFDA Approves 1st Generic EpiPenThinning Retina Seen as Early Warning Sign for Parkinson'sSleep in Your Contacts, Risk Serious Eye Damage: CDCAHA: Wildfire Smoke Threatens Health of Those Near and FarStem Cells Restore Some Vision in Blind MiceHealth Tip: Are You at Risk for Macular Degeneration?Dialysis Linked to Dementia in SeniorsGene Test Predicts Risk of 5 Common DiseasesStudy Hints at Why Women Suffer More Migraines Than MenHealth Tip: Making an Emergency CallHealth Tip: Identify Bug BitesHealth Tip: Most Americans are OverweightA Weak Grip May Signal Future Health Trouble -- Even in KidsEye Disease Link to Alzheimer's SeenNew Research Suggests Glaucoma May Be an Autoimmune DiseaseHealth Tip: Fight Frequent FatigueEarly Onset Type 1 Diabetes Linked to Heart Disease, Shorter LifeAHA: Obesity May Increase Risk for Peripheral Artery DiseaseHealth Tip: Getting a Second Opinion Before SurgeryHealth Tip: Avoid Mosquito BitesPreschoolers' Parents May Be Unprepared to Treat AsthmaSchool Prep Includes Planning Allergy, Asthma ManagementHave Glaucoma and Need to Switch Eye Docs? Here's What You Need to DoHealth Woes Hit 1 in 7 Babies Exposed to Zika in U.S. TerritoriesStudy Urges Genetic Testing of Relatives of Aortic Disease PatientsHepatitis-Infected Kidneys a Safe Option for Transplant: StudySigns Your Child Might Have Hearing LossHow to Keep Foodborne Illness at BayAHA: Air Pollution Exposure Linked to Enlarged HeartsScientists Trace Link Between Head Injuries and Parkinson'sScans Help Spot Heart Trouble Early in People With LupusHealth Tip: Warmer Weather Triggers RashesToo Many Kidney Disease Patients in the Dark About DietGerms Gaining Resistance to Hand Gels in HospitalsHealth Tip: Recognize Signs of a Urinary Tract InfectionMore Research Links Sunscreens to Marine-life DamageLyme Disease Striking More Americans in More StatesClimate Change Means More Deadly Heat Waves: StudyObesity Warps the Shape, Function of Young HeartsHere's What Happened When 1 Unvaccinated NYC Kid Got MeaslesGyms With Tanning Beds Send Mixed MessageSummers Less Smoggy Now, But Winter Air Hasn't ImprovedIt's Hot Outside: How to Stay Safe When Thermometers Rise3-Pronged Approach to Cancer PreventionCould Psoriasis Patients Eat Their Way to Fewer Symptoms?
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Early Promise for Eye Implant to Fight Macular Degeneration

HealthDay News
by By Dennis Thompson
HealthDay Reporter
Updated: Apr 4th 2018

new article illustration

WEDNESDAY, April 4, 2018 (HealthDay News) -- A new stem cell transplant might help preserve or even restore vision being lost to the dry form of age-related macular degeneration, a new pilot clinical trial has shown.

In the experimental therapy, a specially engineered sheet of stem cells is transplanted into the back wall of the eye to replace a layer of cells destroyed by age-related macular degeneration (AMD).

Vision loss appeared to halt in four of the first five people treated with the implant cells, researchers reported in the April 4 issue of the journal Science Translational Medicine.

The fifth patient actually experienced some improvement in vision, and was able to read 17 additional letters off a standard eye chart, said lead researcher Dr. Amir Kashani. He is assistant professor of clinical ophthalmology at the University of Southern California's Keck School of Medicine.

"We didn't really anticipate or expect dramatic improvement in vision," Kashani said. "That was a very encouraging sign."

Two other patients displayed improvement in their ability to focus or fixate on a target better than before surgery, he added.

"They could guide their vision to look at a certain location," Kashani said. "That's one of the prerequisites for being able to read or look somebody in the face, or doing those high-acuity kinds of tasks, so that was also very encouraging."

There currently is no cure or treatment for the dry form of AMD, which accounts for 80 percent to 90 percent of all cases, he noted.

The retina -- the light-sensitive tissue along the back of the eye wall -- is slowly destroyed as a result of AMD. As light-sensing cells die off, people's vision becomes blurry and distorted, and they begin to lose their central vision.

Age-related macular degeneration currently affects approximately 1.7 million Americans, and is projected to affect almost 3 million by 2020. It's a leading cause of severe visual impairment in adults older than 65.

The dry form of AMD involves the loss of a thin layer of cells beneath the retina called retinal pigment epithelium (RPE) cells, Kashani said.

"The function of the RPE cells is to support the overlying retina and its photo sensor cells," Kashani said. Without the nourishment provided by the RPE layer, the retina cannot function normally and begins to die off, permanently damaging vision.

To halt the advance of vision loss, Kashani and his team engineered in the lab a fresh sheet of RPE cells created from embryonic stem cells.

The researchers then implanted the new sheet of cells into the eyes of five patients with long-term dry AMD, in a stage I clinical trial that ultimately will include a total of 20 people.

There were no serious side effects or unanticipated problems in the transplant, Kashani said.

Patients required only a small amount of immune suppression to make sure the body didn't reject the implant. That's because the retina is considered an extension of the brain, and the immune system typically does not target the brain or its related structures, he explained.

"The body doesn't really mount immune responses as we understand them in those areas," Kashani said.

The researchers already are planning a larger series of trials, which they hope will get underway within the next couple of years.

Dr. Avnish Deobhakta is a retina surgeon at the New York Eye and Ear Infirmary of Mount Sinai in New York City. "This type of technology is very exciting considering that it aims to replace the precise layer of cells that are progressively damaged in a form of macular degeneration that affects millions of people and is one of the major causes of irreversible blindness in the U.S.," he said.

"At present, we do not have any effective treatments for the dry form of macular degeneration that results in this sort of retinal atrophy, so this therapy has the potential to change the way we look at this disease and possibly give patients hope that at the very least we can stem the tide of disease progression," Deobhakta added.

More information

The American Academy of Ophthalmology has more about macular degeneration.